| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Tomas J. Heyman is Director at LEGN and has filed Form 4s across 3 companies. Tomas J. Heyman's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.8M at current prices.
The biggest single holding is EXEL (~$3.7M) as Director. The EXEL filings lean toward selling, a net 4,544 shares.
Tomas J. Heyman has 11 Form 4 filings on record from June 2022 to September 2026, across 5 companies: Director at Legend Biotech (LEGN), 2026; Director at Exelixis (EXEL), 2023–2026; Director at AKRO, 2025, and 2 more.
The 16 reported transactions were 5 stock awards, 5 dispositions back to the company, 5 option or other derivative awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $201K.
The only open-market sale was 4,544 shares of EXEL at an average $44.29 on May 21, 2025, about $201K. Twelve months later EXEL was up 14%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 21, 2025 | EXEL Exelixis, Inc. | Director | Sell | 4,544 | $44.29 | $201,253.76 | -12.3% | -14.2% | +13.6% |